Vioxx was taken off the market in 2004.
万络在2004年已经退出市场。
The recent Vioxx debacle bears this out.
最近Vioxx的崩溃证明了这一点。
Could the company someday bring Vioxx back to market?
默克公司会让万络重新投放市场吗？
Compared to placebos, Vioxx and Prexige were associated with twice the risk of heart attack.
与安慰剂相比，万络和鲁米昔布高于其两倍的心脏病风险。
Vioxx was touted as a safer alternative to painkillers such as aspirin when it was introduced in 1998.
1998年默克把罗非考昔推向市场时，曾吹嘘该药是阿司匹林等止痛药更加安全的替代药品。
The findings also support prior research linking rofecoxib (Vioxx) with adverse cardiovascular effects.
该研究也支持以前关于罗非考昔（Vioxx）与心血管副作用相关的结论。
Critics said the FDA should have reacted sooner to signs of problems related to Vioxx and other medicines on the market.
批评家们说FDA本应该早点对万络问题的迹象以及市场上其它的药物问题的迹象作出反应的。
Then in 2004, Merck withdrew its painkiller Vioxx after studies showed the pill increased the risk of heart attacks and strokes.
随后在2004年，在研究显示默克公司的止痛药万络增加了心脏病发作和中风的危险性后，该药撤出了市场。
Vioxx and related pain medications were taken off the market in 2004 because they caused dangerous heart problems in some people.
2004年，万络及与它相关的缓解疼痛的药物被市场撤下，是由于它们会引发一些病人的心脏病。
The civil suit accuses Merck of hiding information about the seriousness of the risks of heart attacks and strokes for patients taking Vioxx.
民事诉讼控告默克公司向服用万络的患者隐瞒了药物致心脏病发作及中风危险的严重性的信息。
In April, the FDA rejected Merck's Arcoxia, anarthritis painkiller in the same drug class as Vioxx, eventhough it is widely available overseas.
4月，FDA否决了默克的关节炎止痛药Arcoxia，Arcoxia和Vioxx是同一类药并在海外已经大量出售了。
The FDA never ordered the drug withdrawn and a subsequent Advisory Committee did not recommend that Vioxx should be barred from returning to market.
FDA从来没有命令药品召回，其下的咨询委员会也没有建议对万络重返市场设置阻碍。
Merck has already turned over at least two million documents in the federal litigation, whose plaintiffs claim Vioxx caused heart attacks and other injuries.
默克公司已经在这一系列诉讼案中递交了两百万份文件，这些案件中的原告都指控万络给他们带来了心脏病和其他损伤。
In addition, researchers looked at the relative cardiovascular risks associated with three other drugs not sold in the U. S., including Vioxx, Arcoxia, and Prexige.
另外，研究人员观察了伴随不在美国销售的其他三种药物的心血管相对风险，其中有万络、托昔布和鲁米昔布。
Investors are also suing Merck, saying it played down the risks of Vioxx and cost them billions of dollars in stock value after the drug was removed from the market.
投资者表示，他们也正在起诉默克制药公司。由于默克制药公司有意淡化了万络的风险，在万络退出市场之后，投资者在股市中损失了数十亿美元。
After Vioxx and other safety controversies, "the American people no longer trust the FDA to protect their health," said Nissen, who has served on FDA advisory panels.
发生了万络和其他安全争议问题之后，“美国民众不在相信FDA能够保护他们的健康，”就职于FDA顾问团的尼森说。
It said the clinical trial had a legitimate scientific purpose in testing the gastrointestinal tolerability of Vioxx compared to the commonly used pain medicine, naproxen.
公司称该临床试验有正当科学目的，是为了比较万络与常用镇痛药萘普生间胃肠耐受性的差别。
The jump wasn't driven by a few high-profile drug problems, such as Merck's withdrawal of painkiller Vioxx in 2004 and Pfizer's suspension of rival painkiller Bextra in 2005.
暴涨不能归因于少数世人瞩目的药物问题，如2004年的默克公司止痛药万络退市和辉瑞公司类似的止痛药Bextra暂停上市。
The chairman of Merck, a giant American drugs firm, got the top job after a safety scandal caused Vioxx, the firm's blockbuster painkiller, to be pulled from the market in 2004.
美国的制药巨头默克公司2004年因安全丑闻将其恶名昭著的止痛药万络召回，随后，迪克·克拉克出任公司董事长。
Merck, based in Whitehouse Station, N. J. , withdrew Vioxx from the market in more than 80 countries in 2004 after a clinical trial showed it doubled the risk of heart attack, stroke and death.
总部设在新泽西州WhitehouseStation的默克公司，在80多个国家，在2004年后的临床试验表明，万若心脏病发作，中风和死亡的风险增加一倍。
Merck, based in Whitehouse Station, N. J. , withdrew Vioxx from the market in more than 80 countries in 2004 after a clinical trial showed it doubled the risk of heart attack, stroke and death.
总部设在新泽西州WhitehouseStation的默克公司，在80多个国家，在2004年后的临床试验表明，万若心脏病发作，中风和死亡的风险增加一倍。
应用推荐